EMD opens Sydney clinic – now in Australia’s four most populated states
Our psychedelic and mental health Investment Emyria (ASX: EMD) just opened its Sydney Empax clinic, with first patients already in treatment.

200 articles
What’s changing in cannabis law: our editors’ articles, and announcements straight from regulators, courts, governments and companies.
Our psychedelic and mental health Investment Emyria (ASX: EMD) just opened its Sydney Empax clinic, with first patients already in treatment.

Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine ( CMND ), spoke on patient access and shared insights from Clearmind’s clinical trial at Yale and Johns Hopkins

Psychedelic-Assisted Therapies Now Reaching Hundreds of Australians as Global Momentum Accelerates

Today, September 1, 2026, marks the beginning of a new chapter for the Oregon Medical Marijuana Program (OMMP) and the Oregon Psilocybin Services (OPS) section as we merge into the Medical Cannabis & Psilocybin (MCAP) section.

On June 29th, Oregon Health Authority announced changes to the Oregon Psilocybin Services (OPS) section.

WASHINGTON — The U.S. Department of Veterans Affairs today announced the launch of a new clinical trial to evaluate the effectiveness and safety of psilocybin to treat major depression in Veterans, including those with concurrent…

Summer is in full swing and so is the CRA’s Social Equity Team! Check out our Quarterly Update and see what we have been up to this summer along with tips and reminders of the resources we offer.

Dr. Alyza Brevard-Rodriguez, founder of The Other Side Dispensary, says Jersey City’s cannabis licensing framework harmed equity operators, disabled veterans, and small business owners

The first quarter (Q1) of 2026 data is now available on the Oregon Psilocybin Services (OPS) Data Dashboard. The OPS Data Dashboard includes pages on licensing, compliance, safety, product and sales, applicant/licensee…
